Metrics as of 10/15/2026, 08:36 AM (Berlin time), refresh in progress.
CRISPR Therapeutics Stock
CRISPR Therapeutics AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Samarth Kulkarni
- Employees
- 393
- Market cap
- $4.8 B
- IPO
- 19/10/2016
CRISPR Therapeutics AG is a healthcare biotechnology company headquartered in Zug, Switzerland. Founded in 2013, the firm focuses on pioneering gene-based medicines for severe diseases by utilizing its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
CRISPR Therapeutics stock: price history
1D
+2.6%
1W
+2.1%
1M
-0.6%
6M
-7.5%
YTD
-1.8%
1Y
-28.3%
2Y
+7.2%
5Y
-46.9%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~17% stronger price swings than usual
Ask the agents about CRISPR Therapeutics
Analyst assessment of CRISPR Therapeutics
PRICE TARGET LOW
US$52.00
CONSENSUS
US$63.17
MEDIAN
US$58.00
PRICE TARGET HIGH
US$80.00
0
STRONG BUY
22
BUY
14
HOLD
2
SELL
0
STRONG SELL
38
TOTAL · Buy
As of: 31/08/2026
CRISPR Therapeutics stock metrics
P/E
-10.82
P/B
2.85
EV/EBITDA
-12.06
RETURN ON EQUITY
-5.2%
NET MARGIN
-895.3%
DEBT/EQUITY
0.45
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.6%
FLOAT SHARES
96,257,536
AVG. DAILY VOLUME (30D)
1,659,990
Insider transactions (SEC)
George Simeon
George Simeon
KASINGER JAMES R.
KASINGER JAMES R.
Kulkarni Samarth
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +2.6%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about CRISPR Therapeutics stock
What does CRISPR Therapeutics do?
CRISPR Therapeutics AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Samarth Kulkarni, the company employs around 393 people.
The IPO was on 19/10/2016; the stock trades on NASDAQ under the ticker CRSP.
What do analysts say about CRISPR Therapeutics stock?
38 analysts rate the stock, the consensus is Buy (as of 31/08/2026).
The average price target is US$63.17, ranging from US$52.00 to US$80.00, with a median of US$58.00.
This is an external assessment, not a statement by Market Jury.
When does CRISPR Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 17% stronger than usual.
Does CRISPR Therapeutics pay a dividend?
No, CRISPR Therapeutics currently does not pay a dividend.
Which stocks are comparable to CRISPR Therapeutics?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get CRISPR Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess CRISPR Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.